In re: Xencor, Inc.
Case Number:
23-2048
Court:
Nature of Suit:
Companies
Sectors & Industries:
-
January 23, 2024
Fed. Circ. Sends Xencor Antibody Patent Case Back To USPTO
The Federal Circuit has granted the U.S. Patent and Trademark Office's bid to send Xencor Inc.'s application for an antibody patent back for further proceedings to a new administrative appellate panel.
-
December 01, 2023
Xencor Scoffs At USPTO Bid To Send Case To Review Panel
Xencor is urging the Federal Circuit to reject what it calls the U.S. Patent and Trademark Office's "eleventh hour" effort to terminate an appeal of a Patent Trial and Appeal Board decision, which backed an examiner's denial of a patent application on antibodies that can be used in autoimmune disease treatments.
-
November 28, 2023
USPTO Wants Antibody Patent Case Sent Back For Review
The U.S. Patent and Trademark Office says the Federal Circuit should terminate Xencor Inc.'s appeal of a Patent Trial and Appeal Board decision that backed an examiner's denial of an application for a patent on antibodies that can be used in autoimmune disease treatments.
-
October 12, 2023
Fed. Circ. Warned USPTO Ruling Threatens Antibody Patents
A U.S. Patent and Trademark Office decision rejecting Xencor Inc.'s application for a patent on antibodies that can be used in autoimmune disease treatments could significantly hinder the ability to obtain antibody patents, legal and medical groups have told the Federal Circuit.